1、novotech-AUGUST 22,2023Hemophilia-Global Clinical Trial LandscapeWorld Federation of Hemophilia(WFH)reported 233,577 cases of hemophilia worldwide,with 185,318 being diag-nosed as Hemophilia A,and 37,998 as Hemophilia BHemophilia prevalence difers globally,with high rates in Europe and Southeast Asi

2、a,and lower rates in other regionsAsia,particularly India and China,takes the lead in terms of hemophilia casesThe US and Europe together comprise around 70,000 global cases of hemophiliaHemophilia primarily afects malesAPAC contributed 35%of hemo-philia trials,led by Mainland China and JapanThe US

3、and Europe conduct-ed 40%of hemophilia trials,with Italy and the UK in the leadEurope showed the shortest trial duration,and the US showed the fastest enrolment rates for hemo-philia trialsIn the past decade,Asia Pacific grew,while the US and Europe declinedHEMOPHILIAGLOBAL CLINICAL TRIAL LANDSCAPE

4、The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech

5、except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribut

6、ion of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-Rare X-linked bleeding disorder with deficient clotting factors(FVIII for A,FIX for B).Hemophilia A comprises 80-85%of